Challenges and opportunities in designing clinical trials for neuromyelitis optica

Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurology
Autors principals: Weinshenker, Brian G., Barron, Gerard, Behne, Jacinta M., Bennett, Jeffery L., Chin, Peter S., Cree, Bruce A.C., de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T., Palace, Jacqueline, Smith, Terry J., Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K., Wasiewski, Warren, Wingerchuk, Dean M., Yeaman, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2015
Matèries:
Views & Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424131/
https://ncbi.nlm.nih.gov/pubmed/25841026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000001520
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars